Patent ID: 8586748

Claim:
A compound formula (I): wherein: Ar is phenyl, naphthyl or heteroaryl selected from indolyl, pyridyl, thienyl, pyrazolyl, oxazolyl, indazolyl, benzimidazolyl, isoquinolinyl, 1H-pyrrolo[2,3-b]pyridinyl, benzothienyl, benzofuranyl, 2,1,3-benzothiadiazolyl and 6H-imidazo[2,1-b]thiazolyl, wherein said phenyl naphthyl or heteroaryl is optionally substituted with one to four groups selected from C 1-6 alkyl, C 1-6 alkoxy, phenyl, heteroaryl, phenyloxy, halogen, —NH 2 , —NHC(O)NH 2 , —NHC(O)C 1-6 alkyl, —NO 2 , —CF 3 , —OCF 3 , —CN, —C(O)C 1-6 alkyl, —(CH 2 ) 0-2 CO 2 C 1-6 alkyl, —(CH 2 ) 0-2 CO 2 H, 5-tetrazolyl, —CHO, —C(O)NH 2 , —C(O)NH(C 1-6 alkyl) and —C(O)N(C 1-6 alkyl) 2 ; or if Ar is phenyl, two adjacent groups together with the phenyl they are bonded to may form a 2,3-dihydrobenzofuranyl, 1,3-dihydroindol-2-one, or 2-acetyl-3,4-dihydro-1H-isoquinolinyl group; Het is a heteroaryl group selected from: and is optionally substituted with one to two groups independently selected from —CN, —NO 2 , halogen, —C 1-6 alkyl, —C(O)NH 2 and CO 2 Me; R 1 and R 2 are independently selected from C 1-6 alkyl, arylC 1-2 alkyl, phenyl, naphthyl and C 3-8 cycloalkyl, wherein said arylC 1-2 alkyl is optionally substituted with one to two groups selected from halogen, C 1-6 alkoxy, C 1-6 alkyl, —CF 3 , imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, 5-methyloxadiazolyl, morpholinyl, piperidinyl and N-methyl-1,2,3,4-tetrahydroisoquinolinyl; or R 1 and R 2 , together with the N they are bonded to form a heterocycle selected from piperidine, morpholine, tetrahydroisoquinoline, decahydroisoquinoline, piperazine, azepane, 6-aza-spiro[2.5]octane, 2,3,4,5-tetrahydro-1H-benzo[b]azepine, [1,4]-diazepane, [1,4]-oxazepane, thiomorpholine, thiomorpholine, thiomorpholine 1,1-dioxide, 4,5,6,7-tetrahydrothieno[3,2-c]pyridine, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine, 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine, 4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridine, 1,2,3,6-tetrahydropyridine and octahydropyrido[1,2-a]pyrazine, wherein said heterocycle is optionally substituted by one to two groups selected from C 1-6 alkyl, C 1-6 alkenyl, phenyl, benzyl, hydroxyC 1-6 alkyl, —OH, —CF 3 , —CN, halogen, —NO 2 , —NH 2 , oxo, 1,3-dioxolane, —CH═NOCH 3 , —SO 2 NH 2 , —SO 2 N(C 1-6 alkyl) 2 , —SO 3 H, —SO 2 (C 1-6 alkyl) 2 , —C(O)N(C 1-6 alkyl) 2 , —C(O)NHC 1-6 alkyl, —(CH 2 ) 0-2 C(O)NH 2 , —(CH 2 ) 0-4 CO 2 H, —(CH 2 ) 0-4 CO 2 C 1-6 alkyl, ═C—CO 2 C 1-6 alkyl, —CH═CH—CO 2 H, —CH═CH—CO 2 C 1-6 alkyl, —OCH 2 CO 2 H, —OCH 2 CO 2 C 1-6 alkyl, —OC(CH 3 ) 2 CO 2 H, —OC(CH 3 ) 2 CO 2 C 1-6 alkyl, —C(O)CH 2 CO 2 H, —C(O)CH 2 CO 2 C 1-6 alkyl, —C(O)C 1-6 alkyl, —C(O)C 1-4 alkyl(OH), —CH 2 OC 1-6 alkyl, —(CH 2 ) 0-2 NHC(O)C 1-6 alkyl, —C(O)morpholinyl, thiazole, 3-methyl-1,2,4-oxadiazolyl, pyrimidine and 2-[1,2,4]oxadiazol-3-ylpyrazine; and R 4 is hydrogen or C 1-6 alkyl; or a pharmaceutically acceptable salt thereof.